Novo Nordisk(CH:NOV)
CHF 173.420.00 (0.00%)
CH:NOV
Novo Nordisk stock forecast
CHF 173.42
At close:0.00 (0.00%)
Novo Nordisk (NOV) Stock Forecast & Price Target
24 Followers
NOV Analyst Ratings
Hold
0Buy10Hold3Sell
Based on 13 analysts giving stock ratings to Novo Nordisk in the past 3 months
NOV Stock 12 Month Forecast
Average Price Target
CHF 35.60▼(-79.47% Downside)Based on 13 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is CHF 35.60 with a high forecast of CHF 43.17 and a low forecast of CHF 27.50. The average price target represents a -79.47% change from the last price of CHF 173.41.
Past 12 Months12 Month ForecastJan2026Oct2026
HighCHF 43.17
AverageCHF 35.60
LowCHF 27.50
Highest Price TargetHighestCHF 43.17Average Price TargetCHF 35.60Lowest Price TargetLowestCHF 27.50
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Emmanuel Papadakis | Deutsche Bank | CHF 29.60 | sell | -82.93%Downside | Reiterated | 11/11/26 | ||
| Justin Smith | Bernstein | CHF 25.04→CHF 27.50 | sell | -84.14%Downside | Reiterated | 11/06/26 | ||
| James Quigley | Goldman Sachs | CHF 35.77→CHF 37.49 | hold | -78.38%Downside | Reiterated | 11/05/26 | ||
| Matthew Weston | UBS | CHF 40.95→CHF 38.48 | hold | -77.81%Downside | Reiterated | 11/05/26 | ||
| Graham Parry | Citi | CHF 36.51→CHF 36.75 | hold | -78.81%Downside | Reiterated | 11/05/26 | ||
| Michael Leuchten | Jefferies | CHF 33.92 | hold | -80.44%Downside | Reiterated | 11/04/26 | ||
| Richard Vosser | J.P. Morgan | CHF 33.92 | hold | -80.44%Downside | Reiterated | 11/04/26 | ||
| Sachin Jain | Bank of America Securities | CHF 43.17 | hold | -75.11%Downside | Reiterated | 11/04/26 | ||
| Kerry Holford | Berenberg Bank | CHF 37.62 | hold | -78.31%Downside | Reiterated | 09/22/26 | ||
| Thibault Boutherin | Morgan Stanley | CHF 30.83 | sell | -82.22%Downside | Downgraded | 09/11/26 | ||
| Rajesh Kumar | HSBC | CHF 37.00→CHF 39.47 | hold | -77.24%Downside | Reiterated | 09/10/26 | ||
| James Gordon CFA | Barclays | CHF 38.23→CHF 37.00 | hold | -78.66%Downside | Reiterated | 09/08/26 | ||
| Nico Chen | DBS | CHF 37.00 | hold | -78.66%Downside | Reiterated | 08/25/26 | ||
| Elmar Kraus | DZ BANK AG | ― | hold | ― | Reiterated | 08/07/26 | ||
| Martin Brenoe | Nordea Markets | CHF 43.17 | buy | -75.11%Downside | Upgraded | 06/19/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Emmanuel PapadakisDeutsche Bank | SellReiteratedCHF 29.60 | 11/11/26 | -82.93%Downside | ||
| Justin SmithBernstein | SellReiteratedCHF 25.04→CHF 27.50 | 11/06/26 | -84.14%Downside | ||
| James QuigleyGoldman Sachs | HoldReiteratedCHF 35.77→CHF 37.49 | 11/05/26 | -78.38%Downside | ||
| Matthew WestonUBS | HoldReiteratedCHF 40.95→CHF 38.48 | 11/05/26 | -77.81%Downside | ||
| Graham ParryCiti | HoldReiteratedCHF 36.51→CHF 36.75 | 11/05/26 | -78.81%Downside | ||
| Michael LeuchtenJefferies | HoldReiteratedCHF 33.92 | 11/04/26 | -80.44%Downside | ||
| Richard VosserJ.P. Morgan | HoldReiteratedCHF 33.92 | 11/04/26 | -80.44%Downside | ||
| Sachin JainBank of America Securities | HoldReiteratedCHF 43.17 | 11/04/26 | -75.11%Downside | ||
| Kerry HolfordBerenberg Bank | HoldReiteratedCHF 37.62 | 09/22/26 | -78.31%Downside | ||
| Thibault BoutherinMorgan Stanley | SellDowngradedCHF 30.83 | 09/11/26 | -82.22%Downside | ||
| Rajesh KumarHSBC | HoldReiteratedCHF 37.00→CHF 39.47 | 09/10/26 | -77.24%Downside | ||
| James Gordon CFABarclays | HoldReiteratedCHF 38.23→CHF 37.00 | 09/08/26 | -78.66%Downside | ||
| Nico ChenDBS | HoldReiteratedCHF 37.00 | 08/25/26 | -78.66%Downside | ||
| Elmar KrausDZ BANK AG | HoldReiterated | 08/07/26 | ― | ||
| Martin BrenoeNordea Markets | BuyUpgradedCHF 43.17 | 06/19/26 | -75.11%Downside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Novo Nordisk
3 Months
Success Rate41/68 ratings generated profit
60%
Average Return
+1.84%
Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 60.29% of your transactions generating a profit, with an average return of +1.84% per trade.
1 Year
Success Rate39/68 ratings generated profit
57%
Average Return
+8.11%
Copying Emmanuel Papadakis's trades and holding each position for 1 Year would result in 57.35% of your transactions generating a profit, with an average return of +8.11% per trade.
2 Years
Success Rate31/68 ratings generated profit
46%
Average Return
+11.41%
Copying Emmanuel Papadakis's trades and holding each position for 2 Years would result in 45.59% of your transactions generating a profit, with an average return of +11.41% per trade.
NOV Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 0 | 0 | 0 |
| Hold | 27 | 25 | 29 | 27 | 20 |
| Sell | 2 | 2 | 7 | 8 | 9 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 31 | 29 | 36 | 35 | 29 |
In the current month, NOV has received 0 Buy Ratings, 20 Hold Ratings, and 9 Sell Ratings. NOV average Analyst price target in the past 3 months is 35.60.
NOV Financial Forecast
HighCHF 0.64
ConsensusCHF 0.56
LowCHF 0.40
NOV Earnings Forecast
Next quarter’s earnings estimate for NOV is CHF 0.56 with a range of CHF 0.40 to CHF 0.64. The previous quarter’s EPS was CHF 0.71. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
HighCHF 10.3B
ConsensusCHF 9.71B
LowCHF 8.9B
NOV Sales Forecast
Next quarter’s sales forecast for NOV is CHF 9.71B with a range of CHF 8.90B to CHF 10.26B. The previous quarter’s sales results were CHF 9.77B. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
NOV Stock Forecast FAQ
What is CH:NOV’s average 12-month price target, according to analysts?
Based on analyst ratings, Novo Nordisk’s 12-month average price target is CHF35.60.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Novo Nordisk a Buy, Sell or Hold?
Novo Nordisk has a consensus rating of Hold, which is based on 0 buy ratings, 10 hold ratings and 3 sell ratings.
What is Novo Nordisk’s share price target?
The average share price target for Novo Nordisk is CHF35.60. This is based on 13 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF43.17, and the lowest forecast is CHF27.50. The average share price target represents a 79.47% decrease from the current price of CHF173.415.
What do analysts say about Novo Nordisk?
Novo Nordisk’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Street analysts.
How can I buy shares of Novo Nordisk?
To buy shares of CH:NOV, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
